← United States · Coverage record
US · SEC FORM 4
IDEAYA Biosciences, Inc.
IDYA · Nasdaq · CIK 0001676725 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
5 Form 4 transaction lines observed in the same window
3 sales · 2 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-02 · Stein Jeffrey.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 9,183,217
- Previous report
- 9,931,622
- Avg daily volume
- 1,088,895
- Days to cover
- 8.4
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-02 | Stein Jeffrey | Purchase (P) | Common Stock | 50,000 | USD 32.96 | USD 1,648,000 | SEC filing ↗ |
| 2020-06-30 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 2,531 | USD 13.32 | USD 33,713 | SEC filing ↗ |
| 2020-06-22 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 19,732 | USD 13.93 | USD 274,867 | SEC filing ↗ |
| 2020-06-19 | BIOTECHNOLOGY VALUE FUND II LP; BIOTECHNOLOGY VALUE FUND L P; BVF GP HOLDINGS LLC; BVF I GP LLC; BVF II GP LLC; BVF INC/IL; BVF PARTNERS L P/IL; BVF Partners OS Ltd.; Biotechnology Value Trading Fund OS LP; LAMPERT MARK N | Purchase (P) | Common Stock, $0.0001 par value | 98,264 | USD 14.39 | USD 1,414,019 | SEC filing ↗ |
Form 4 evidence
8 transaction lines in the latest 365-day window; 160 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Hata Yujiro S | Sale (S) | Common Stock | 26,338 | USD 37.41 | USD 985,397 | SEC filing ↗ |
| 2026-10-06 | Hata Yujiro S | Option exercise / conversion (M) | Common Stock | 26,338 | USD 4.31 | USD 113,517 | SEC filing ↗ |
| 2026-07-07 | Ruiz Briseno Andres | Sale (S) | Common Stock | 9,550 | USD 40.01 | USD 382,096 | SEC filing ↗ |
Show recent Form 4 evidence (7 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Hata Yujiro S | Sale (S) | Common Stock | 26,338 | USD 37.41 | USD 985,397 | SEC filing ↗ |
| 2026-10-06 | Hata Yujiro S | Option exercise / conversion (M) | Common Stock | 26,338 | USD 4.31 | USD 113,517 | SEC filing ↗ |
| 2026-07-07 | Ruiz Briseno Andres | Sale (S) | Common Stock | 9,550 | USD 40.01 | USD 382,096 | SEC filing ↗ |
| 2026-07-07 | Ruiz Briseno Andres | Option exercise / conversion (M) | Common Stock | 9,550 | USD 12.86 | USD 122,813 | SEC filing ↗ |
| 2026-03-02 | Stein Jeffrey | Purchase (P) | Common Stock | 50,000 | USD 32.96 | USD 1,648,000 | SEC filing ↗ |
| 2025-11-28 | Snyder Douglas B. | Award / grant (A) | Common Stock | 1,041 | USD 16.91 | USD 17,603 | SEC filing ↗ |
| 2025-11-28 | Ruiz Briseno Andres | Award / grant (A) | Common Stock | 1,253 | USD 16.91 | USD 21,188 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | IDYA |
| CIK | 0001676725 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 160 transaction lines from 2020-03-30 to 2026-10-06 10 P purchase lines · 86 S sale lines · 64 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.